Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Kalma

Kalma is a medicine containing the active ingredient(s) alprazolam. On this page you will find out more about Kalma, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: alprazolam

Over 65 years of age?

If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Kalma 2 mg uncoated tablet, 50

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Anxiety. Short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. Panic disorder. The treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. The diagnostic criteria for panic disorder in DSM-III-R are as follows: The panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. Later in the course of this disturbance, certain situations (eg. driving a car or being in a crowded place) may become associated with having a panic attack. These panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). The diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. The panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. NOTE: Attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. At least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. The panic attack must not be attributable to some known organic factor, eg. amphetamine or caffeine, intoxication, hyper-thyroidism. The efficacy of alprazolam in conditions where the above criteria are not met has not been established. The risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. Although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. The results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. The physician should periodically reassess the usefulness of the drug for each patient. A comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. Alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p<0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. Panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. Psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. Prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance 15.2mm x 4.55mm oblong, bevel-edged, white triple scored tablet debossed "AL" on one side, "G2" on the other side.

Images are the copyright of the Pharmacy Guild of Australia

Dosage Form Tablet, uncoated
Route of administration Oral
Medicine schedule
50 tablets: Controlled Drug

There is one type of pack available.

Pack type 1
Pack type 1
Type Bottle
Storage temperature Store below 25 degrees Celsius
Storage conditions No information available
Life time 3 Years
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 6 results

Kalma Tablets -

Kalma Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Benzodiazepines/Tranquilisers - BluePages

Find out if tranquillisers are likely to help.

Read more on e-hub Web Services - Australian National University (ANU) website

Clarithro 250 Tablets -

Clarithro 250 Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Movox Tablets -

Movox Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Clarithromycin Sandoz Tablets -

Clarithromycin Sandoz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Crixivan Capsules -

Crixivan Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo